501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy

Background

For locally advanced unresectable NSCLC, studies of PD-1 inhibitor plus chemo as induction therapy and its roles in subsequent surgical resection are still limited. In this study, a consecutive series of unresectable stage III NSCLC patients were collected to investigate the surgical outcome and survival outcomes in locally advanced patients who received preoperative chemotherapy combined with immunotherapy.

Methods

92 locally advanced NSCLC patients received 2-4 cycles of chemotherapy combined with immunotherapy. Surgical rates, major pathologic remissions(MPR), pathologic complete remissions(PCR), postoperative complications, and immune-related adverse reactions(irAEs) were assessed. Disease-free survival(DFS) and overall survival(OS) were analyzed in 45 patients who were followed up at least one year after the surgery.

Results

71.74% of patients underwent surgical resection. 63.64% (42/66) achieved MPR and PCR, of which 37.87% (25/66) were PCR. 26.09% of patients developed irAEs, the most common was skin toxicity, followed by thyroid dysfunction. Of the 47 patients who received the surgery more than one year, only 4.3%(2/47) of patients lost the followed-up. 8 patients suffered from recurrence and 4 were died of the disease. One year disease-free survival rate was 88.9%(40/45) and one year over-all survival rate was 97.8%(44/45).

Conclusions

Preoperative chemotherapy combined with immunotherapy provides more opportunities for radical resection and acceptable survival outcomes in unresectable locally advanced NSCLC patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Xin Wang.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.